About Global Blood Therapeutics
Global Blood Therapeutics focuses on developing treatments for sickle cell disease (SCD), a genetic blood disorder that affects hemoglobin in red blood cells. Their main product, Oxbryta (voxelotor), is an FDA-approved treatment for SCD patients aged 4 and older. The company conducts extensive research, clinical trials, and seeks regulatory approvals to introduce new therapies. Unlike many competitors, GBT emphasizes community advocacy and aims to transform the treatment landscape for SCD. Their goal is to improve the lives of patients with SCD through effective therapies and ongoing support.
San Francisco, CaliforniaHeadquarters
2011Year Founded
$86.3MTotal Funding
ACQUISITIONCompany Stage
Biotechnology, HealthcareIndustries
501-1,000Employees
Risks
Increased competition from gene-editing therapies by CRISPR and Vertex.
Potential generic competition may reduce pricing power for voxelotor.
Integration with Pfizer may cause organizational disruptions affecting efficiency.
Differentiation
GBT focuses on innovative treatments for sickle cell disease, a niche market.
Oxbryta is FDA-approved for patients as young as 4, showing pediatric commitment.
GBT's strong community advocacy differentiates it in patient-centric care models.
Upsides
Pfizer acquisition provides GBT with significant resources for R&D and market expansion.
FDA's fast-track designation supports rapid development of GBT's innovative therapies.
AI in drug discovery could enhance GBT's R&D efforts for rare diseases.
Funding
Total raised$86.28 M
Latest valuation$5.40 B
StageACQUISITION
ACQUISITION
7/31/2022$5.4 K
$5.40 BSERIES B
12/31/2014$48
$240.00 MSERIES A
5/31/2012$41
$203.50 M